RxDoctor Payments Data

Yili Huang, DO

Pain Medicine · New Haven, CTNPI 1225324429

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $11,000 of the $17,670 with a category attached, or 62.3%. Sanofi-aventis U.S. LLC accounts for 86.9% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $9,368 and has fallen 97.7% since, to $212 in 2025. Among pain medicine clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$17,670in general payments, 2019–2025

Across 58 payments — averaging $304.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$15K
  • GSK$764
  • Boston Scientific$373
  • AbbVie$281
  • Esperion Therapeutics, Inc.$139
  • Abiomed$138
  • plus $616 from 6 others

What the payments were for

  • Consulting fees$4,36025%
  • Speaking & faculty fees$11,00062%
  • Food & beverage$2,31013%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,670 in reported general payments places this provider in the 90th percentile of 69 pain medicine providers in Connecticut.

See all pain medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$303,702
Medicare patients
382
Services billed
4,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin345$4,834
Tizanidine Hcl119$1,290
Duloxetine Hcl60$544
Diclofenac Sodium17$488
Methocarbamol17$154
Cyclobenzaprine Hcl16$82

Paid to pharmacies, not to this prescriber.

Other pain medicine in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →